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Introduction
Methicillin-Resistant Staphylococcus aureus (MRSA) is one of 
the most prevalent, pathogenic antimicrobial-resistant organisms, 
causing invasive infections worldwide [1]. MRSA has become a leading 
cause of pneumonia in both healthcare and community settings [2,3]. 
Furthermore, approximately 69% of adults in the United States (US) 
are either overweight or obese [4], which is concerning as obesity is an 
independent risk factor for developing pneumonia [5,6]. 
Limited treatment options exist for patients with MRSA 
pneumonia, and for many years, vancomycin, a glycopeptide 
antibiotic that inhibits Gram-positive bacterial cell wall synthesis by 
binding a D-alanyl-D-alanine cell wall precursor that is essential for 
peptidoglycan cross-linking, has served as the standard of care [7-9]. 
However, over time, clinical outcomes among vancomycin-treated 
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Abstract
Background: Methicillin-Resistant Staphylococcus aureus (MRSA) has become a leading cause of pneumonia 
in the United States and there is limited data on treatment outcomes in obese patients.We evaluated the effectiveness 
of linezolid compared to vancomycin for the treatment of MRSA pneumonia in a national cohort of obese Veterans.
Methods: This retrospective cohort study included obese patients (body mass index ≥ 30) admitted to Veterans 
Affairs hospitals with MRSA-positive respiratory cultures and clinical signs of infection between 2002 and 2012. 
Patients initiating treatment with either vancomycin or linezolid, but not both, were selected for inclusion. Propensity 
matching and adjustment of Cox proportional hazards regression models quantified the effect of linezolid compared 
with vancomycin on time to hospital discharge, intensive care unit discharge, 30-day mortality, inpatient mortality, 
therapy discontinuation, therapy change, 30-day readmission, and 30-day MRSA reinfection. We performed 
sensitivity analyses by vancomycin Minimum Inhibitory Concentrations (MICs) and true trough levels.
Results: We identified 101 linezolid and 2,565 vancomycin patients. Balance in baseline characteristics 
between the treatment groups was achieved within propensity score quintiles and between propensity matched pairs 
(76 pairs). No significant differences were observed for the outcomes assessed. Among patients with vancomycin 
MICs of ≤ 1 μg/mL, the linezolid group had a significantly lower mortality rate, increased length of hospital stay, 
and longer therapy duration. There were no differences between the linezolid and vancomycin MICs of ≥ 1.5 μg/
mL groups. Clinical outcomes among those with vancomycin trough concentrations of 15-20 mg/L were similar to 
patients treated with linezolid.
Conclusions: In our real-world comparative effectiveness study among obese patients with suspected MRSA 
pneumonia, linezolid was associated with a significantly lower mortality rate as compared to the vancomycin-treated 
patients with lower vancomycin MICs. Further studies are needed to determine whether this beneficial effect is 
observed in other study populations.
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patients with MRSA pneumonia have worsened [10]. In addition, the 
use of the vancomycin in MRSA pneumonia has been questioned due 
to poor penetration into alveolar fluid and the emergence of bacteria 
with decreased vancomycin susceptibility [2,7,10]. These limitations 
have prompted the need for additional therapeutic options. Linezolid, 
an oxazolidinone antibiotic that inhibits protein synthesis at the 50S 
ribosome, is recommended for the treatment of pneumonia caused by 
Staphylococcus aureus (methicillin-susceptible and resistant strains) 
bacteria [11]. While linezolid has been shown to achieve high lung 
concentrations, there is limited evidence to support clinical superiority 
over vancomycin [10,12-15]. Moreover, the optimal treatment in obese 
patients is largely unknown.
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Obesity is associated with an increased risk of pneumonia [5,6]. 
Decreased immunity, a higher risk of aspiration, reduced lung volume, 
and an altered ventilation pattern, impact pneumonia risk in obese 
patients [5,6]. Furthermore, obesity itself is an independent predictor 
of antibiotic treatment failure [16]. To date, there is no published 
research comparing linezolid and vancomycin in obese patients 
with MRSA pneumonia in the real-world clinical setting. Due to the 
increasing complexity of treating MRSA pneumonia, controversial 
superiority data, and the scarcity of data in the obese, we sought to 
evaluate the effectiveness of linezolid therapy compared to vancomycin 
for the treatment of suspected MRSA pneumonia in a national cohort 
of obese Veterans.
Materials and Methods
Data sources
The Veterans Health Administration has utilized an electronic 
medical record system since 1999 [17]. Our study included national 
standardized databases capturing patient care including International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-
CM) diagnostic and procedure codes, microbiology results, pharmacy 
records for prescriptions and barcode administration, laboratory 
results, vital status, and vital signs.
Study population
We conducted a national retrospective cohort study quantifying 
the effectiveness of linezolid compared to vancomycin among obese 
patients with suspected MRSA pneumonia. We identified hospital 
in patients with positive MRSA cultures from a pulmonary site 
between January 1, 2002 and December 1, 2012. Patients exposed 
to at least 1 day of therapy with linezolid (intravenous or oral) or 
vancomycin (intravenous only) were selected for inclusion. Next we 
identified all obese patients with a body mass index (BMI) ≥ 30 [18]. 
BMI calculations were based on the most recent height and weight 
measurements within a year of treatment initiation. Additionally, we 
included patients initiating linezolid or vancomycin therapy within a 
window of 3 days prior to culture through 4 days after culture with 
an absence of linezolid or vancomycin therapy in the 7 days prior to 
treatment initiation.
Of the patients with culture-positive MRSA treated with either 
linezolid or vancomycin, an additional inclusion criterion included 
clinical signs of infection based on the presence of a chest x-ray, or a 
fever, or an elevated white blood cell count [3,19]. Each clinical sign 
was assessed between the admission date and treatment initiation date. 
Fever was defined as a temperature ≥ 100.4⁰F. An elevated white blood 
cell count was defined as ≥10,000/mm3. We excluded patients who died 
or were discharged within 2 days of treatment initiation and patients 
exposed to more than 2 consecutive days of other antibiotic therapy 
with activity against MRSA (clindamycin, daptomycin, doxycycline, 
linezolid, minocycline, tigecycline, trimethoprim/sulfamethoxazole, 
vancomycin) in the 3 days prior to or during treatment with linezolid 
or vancomycin. Only the first admission within the study period 
meeting all inclusion and exclusion criteria was included. The purpose 
of the exclusion criteria were three-fold, to identify patients: (1) with 
clinical signs of infection in addition to a positive culture, (2) who were 
still in the hospital the day after treatment initiation, and (3) treated 
with monotherapy.
Outcomes
The primary outcome of interest was time to hospital discharge. 
Therapy initiation was used to define the index date of treatment. 
Time calculations were made from the index date to the event date 
for each endpoint. The secondary endpoints of interest included 
time to Intensive Care Unit (ICU) discharge, 30-day mortality, 
inpatient mortality, therapy discontinuation, therapy change, 30-day 
readmission, and 30-day MRSA reinfection. For hospital discharge, 
patients who died during the admission were censored on their date of 
death. Transfer out of an ICU was assessed among patients initiating 
linezolid or vancomycin therapy in the ICU. 
Antimicrobial drug exposures with activity against MRSA were 
assessed for each patient during the admission. These exposures 
were classified into dichotomous variables based on the class of the 
antimicrobial agent and by the duration of receipt of agents in each 
class. Therapy change was defined as discontinuation of linezolid 
or vancomycin and initiation of another agent with anti-MRSA 
activity. As such, therapy change could have included switching from 
linezolid to vancomycin, switching from vancomycin to linezolid, or 
switching from either linezolid or vancomycin to another anti-MRSA 
antibiotic (listed above). Switching an antibiotic (i.e. linezolid) from 
an intravenous to an oral route was not considered a therapy change. 
Clinical rationale for therapy change, such as de-escalation resulting 
from clinical improvement or change in therapy as a result of failure 
was not ascertained. For 30-day readmission to a VA medical unit 
and 30-day MRSA reinfection, patients who died after discharge were 
censored on their date of death. The end of the follow-up period was 
December 31, 2012.
Statistical analysis
To assess baseline differences between the two study groups, we 
utilized a Fisher’s exact or χ2 test for categorical data. For continuous 
variables of interest, we used a t-test for normally distributed data and 
the non-parametric Wilcoxon Rank Sum test was used otherwise. We 
employed propensity score methods, where the predicted probability 
of treatment with linezolid was derived from an unconditional logistic 
regression model using a manual backward, non–computer-generated, 
elimination approach [20-22]. Propensity score stratification and 
matching within propensity score calipers were implemented, related 
assumptions were assessed, and subsequent covariate balance was 
reviewed [20,21].
In the second stage of modeling, we used Cox proportional hazards 
regression models to quantify the effect of linezolid treatment in obese 
patients with MRSA pneumonia compared to vancomycin on the 
aforementioned outcomes. We further evaluated Cox proportional 
hazards model assumptions, including that of proportionality, with 
formal tests and graphical displays [23]. If the confidence interval of 
the hazard ratio included one, then the clinical outcome occurred 
at comparable rates in both the linezolid and vancomycin groups. 
A hazard ratio greater than one indicated an increased probability 
of the event occurring sooner in the linezolid group compared to 
the reference vancomycin group. In terms of the study outcomes, a 
hazard ratio greater than one would represent a higher mortality rate, 
decreased length of stay, or a higher readmission rate among patients 
treated with linezolid. Alternatively, a hazard ratio less than one would 
mean time to mortality was lower and length of stay was higher in the 
linezolid group as compared to vancomycin.
We conducted subgroup analyses among patients with morbid 
obesity (BMI ≥ 40) and with positive Bronchoalveolar Lavage (BAL) 
cultures. Additionally, we assessed the study outcomes among a 
restricted study population of those with a pneumonia-related diagnosis 
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code present during the hospital admission (ICD-9-CM codes 003.22, 
020.3, 020.4, 020.5, 021.2, 022.1, 031.0, 039.1, 052.1, 055.1, 073.0, 083.0, 
112.4, 114.0, 114.4, 114.5, 115.05, 115.15, 115.95, 130.4, 136.3, 480-486, 
513.0, 517.1) [24]. 
We also performed several sensitivity analyses. First, we assessed 
linezolid effectiveness as compared to patients with vancomycin 
minimum inhibitory concentrations (MICs) of ≤ 1 μg/mL and those 
with vancomycin MICs of ≥ 1.5 μg/mL. Second, we assessed linezolid 
effectiveness as compared to patients with true vancomycin trough 
concentrations of 15-20 mg/L and no evidence of acute kidney injury 
(defined as an increase in serum creatinine of 0.3 mg/dL or 50% prior 
to starting vancomycin) [25]. True vancomycin troughs were defined 
as levels obtained at steady state, with at least 3 vancomycin doses 
before the level, that were taken less than 2 hours before the next 
vancomycin dose or within 2 hours of the average interval between 
the two prior vancomycin doses [25]. Only the first trough level after 
the third vancomycin dose which met our steady state definition was 
assessed. We did not assess change in vancomycin dosing based on 
trough results. All analyses were performed using SAS (SAS Institute 
Inc., Cary, NC,Version 9.3).
Results
We identified 2,666 obese patients with suspected MRSA 
pneumonia who met our inclusion and exclusion criteria (Figure 1). 
There were 2,565 (96.2%) patients in the vancomycin group and 101 
(3.8%) in the linezolid group. Among those treated with linezolid, 
approximately 91% (n=92) were dosed twice daily. The mean patient 
age at the time of culture collection was 66 years for linezolid and 
68 years for vancomycin (Table 1). Several statistically significant 
differences in the frequency of current comorbidities, present during 
the suspected MRSA pneumonia admission, were observed, including 
chronic ulcer, dialysis, rheumatoid arthritis, and cerebrovascular 
disease. Medical histories in the year prior to the suspected MRSA 
pneumonia hospitalization, including pneumonia, osteomyelitis, and 
allergy to vancomycin, differed significantly between the treatment 
groups. Patients in the linezolid group had higher utilization of linezolid 
in the 90 days prior to the suspected MRSA pneumonia hospitalization 
(Table 2). Furthermore, surgical procedures in the previous 90 days 
and MRSA bronchial culture sites were more common in the linezolid 
group compared to the vancomycin group. 
Though differences in baseline variables were observed between 
the treatment groups, balance was achieved within propensity score 
quintiles and between propensity matched pairs (linezolid=76, 
vancomycin=76). In propensity score quintile adjustment, quintile I 
served as the reference. Propensity score matching was achieved within 
0.001 caliper. The propensity score model can be found in the footnote 
of Table 3. This model demonstrated excellent discrimination between 
the treatment groups (C-statistic 0.84) [22].
The median time to discharge was 15 days (interquartile range 
[IQR] 7-30) among linezolid-treated patients versus 12 days (IQR 7-23) 
in vancomycin-treated patients. Time to discharge was significantly 
longer in the linezolid group compared to the vancomycin group in the 
unadjusted analysis (hazard ratio [HR] 0.76, 95% confidence interval 
[CI] 0.60-0.96) and non-significantly longer in propensity adjusted (HR 
0.85, 95% CI 0.66-1.08) and propensity matched analyses (HR 0.96, 
95% CI 0.56-1.65; Table 3). The inpatient mortality (28%) and 30-day 
mortality (28%) rates were high but similar between treatment groups 
among this obese cohort with positive MRSA pulmonary cultures. 
No significant differences were observed in unadjusted, adjusted, or 
matched Cox proportional hazards models for time to ICU discharge, 
30-day mortality, inpatient mortality, therapy discontinuation, therapy 
change, 30-day MRSA pneumonia reinfection, or 30-day readmission.
Results similar to the overall cohort were observed in subgroup 
analyses among morbidly obese patients (BMI ≥ 40; linezolid n=29, 
vancomycin n=562) and those with positive BAL cultures (linezolid 
n=13, vancomycin n=165). Time to hospital discharge in the morbidly 
obese was significantly longer in the linezolid group in the unadjusted 
(HR 0.50, 95% CI 0.32-0.79) and propensity adjusted (HR 0.51, 95% 
CI 0.32-0.81) analyses and non-significant in propensity matched 
analyses (HR 0.50, 95% CI 0.15-1.66). No significant differences were 
observed for the other outcomes or by BAL subgroup. Regarding the 
subgroup analysis among patients with a pneumonia diagnosis code 
(linezolid n=67, vancomycin n=1,612), patients treated with linezolid 
demonstrated a significantly lower rate of therapy discontinuation 
(propensity matched HR 0.42, 95% CI 0.20-0.87) compared to patients 
treated with vancomycin, indicating length of therapy was longer in the 
vancomycin group.
Among the vancomycin group, we identified 984 eligible patients 
(38%) for the sensitivity analyses evaluating effectiveness by vancomycin 
MICs. Of them, 85% (n=833) had vancomycin MICs ≤ 1 μg/mL, 1% 
(n=10) had a MIC=1.5 μg/mL, 14% (n=141) had a MIC=2 μg/mL, 
and no patients had MICs > 2 μg/mL. Patients on linezolid showed 
significantly lower rates of 30-day mortality (Table 4; propensity 
matched HR 0.35, 95% CI 0.14-0.90) and therapy discontinuation 
(propensity matched HR 0.49, 95% CI 0.27-0.87) than those with 
vancomycin MICs of ≤ 1 μg/mL, meaning linezolid patients had longer 
survival in the 30 days after discharge and a longer duration of therapy 
than vancomycin patients with MICs of ≤ 1 μg/mL. Time to hospital 
discharge was significantly longer in the linezolid group compared to 
the vancomycin group with MICs of ≤ 1 μg/mL (unadjusted HR 0.69, 
95% CI 0.54-0.89; propensity adjusted HR 0.72, 95% CI 0.55-0.93; and 
propensity matched HR 0.52, 95% CI 0.29-0.93).
Only 12% (n=301) of vancomycin patients had accurately obtained 
through concentrations without evidence of acute kidney injury. In 
sensitivity analyses among these patients with vancomycin trough 
levels obtained at steady state, 19% (n=58) had therapeutic trough 
concentrations less than 10 mg/L, 29% (n=86) had 10-15 mg/L, 22% 
(n=66) had 15-20 mg/L, and 30% (n=91) had greater than or equal 
to 20 mg/L. All clinical outcomes were similar among linezolid 
patients as compared to vancomycin patients with vancomycin trough 
concentrations between 15-20 mg/L.
Discussion
To our knowledge, this is the first real-world comparative 
effectiveness study assessing linezolid and vancomycin for the treatment 
of suspected MRSA pneumonia in obese patients. Rates of hospital 
discharge, ICU discharge, 30-day mortality, inpatient mortality, 
therapy discontinuation, therapy change, 30-day MRSA pneumonia 
reinfection, and 30-day readmission did not differ significantly between 
linezolid and vancomycin in our study. 
Our results agree with a recently published analysis of two linezolid 
clinical trials in which clinical success and microbiologic success were 
similar across all quartiles of weight in patients with nosocomial MRSA 
pneumonia [26]. This appears to be the only other study evaluating 
clinical outcomes among obese MRSA pneumonia patients treated with 
linezolid or vancomycin. Additionally, our findings are consistent with 
previous research comparing linezolid and vancomycin in non-obese 
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MRSA: Methicillin-Resistant Staphylococcus; BMI: Body Mass Index 
Adult (≥18 years) inpatients with positive MRSA cultures from 
pulmonary sites between 2002-2012 
N=28,692 
• No treatment initiation with 
linezolid or vancomycin in 3 days 
prior to culture or 4 days after 
culture (N=10,597) 
At least one record of linezolid or vancomycin within an 8-day 
window from culture date (-3 days to +4 days)  
N=18,095 
• BMI < 30 or BMI missing 
(N=13,492) 
Obese (BMI ≥ 30) patients 
N=4,603 
• History of linezolid or 
vancomycin use in the 7 days 
prior to treatment initiation 
(N=1,199) 
No history of linezolid or vancomycin use in the 7 days prior to 
treatment initiation 
N=3,404 
Clinical signs of infection based on the presence of a chest x-
ray, or a fever ≥ 100.4 F, or leukocytosis > 10,000/mm
3
  
N=3,229 
• No clinical signs of infections 
(N=175) 
• Death or discharge within 2 days 
of treatment initiation (N=330) 
• Combination therapy (N=233) 
No death or discharge within 2 days of treatment initiation and 
linezolid or vancomycin monotherapy  
N=2,666 
Linezolid  
N=101 
Vancomycin 
N=2,565 
Excluded 
Figure 1: Study Cohort Identification
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Demographic characteristics LinezolidN=101
Vancomycin
N=2,565 P-value
Age (years) 66.2 ± 12.3 67.6 ± 11.2 0.22
Male 98 (97.0) 2,489 (97.0) 0.99
Body mass index
0.15
30-35 63 (62.4) 1,652 (64.4)
35-40 9 (8.9) 351 (13.7)
40+ 29 (28.7) 562 (21.9)
Current comorbid conditions1)
Charlson score 3.7 ± 2.7 3.6 ± 2.5 0.84
Elixhauser score 4.7 ± 2.5 4.3 ± 2.0 0.18
Chronic renal disease 34 (33.7) 718 (28.0) 0.21
Peripheral vascular disease 9 (8.9) 236 (9.2) 0.92
Cancer 17 (16.8) 487 (19.0) 0.59
Cerebrovascular disease 6 (5.9) 363 (14.2) 0.02*
Congestive heart failure 43 (42.6) 1,031 (40.2) 0.63
Diabetes 53 (52.5) 1,196 (46.6) 0.25
Rheumatoid arthritis 5 (5.0) 27 (1.1) < 0.001*
Hypertension 53 (52.5) 1,532 (59.7) 0.15
Hypothyroidism 10 (9.9) 148 (5.8) 0.08
Coagulopathy 6 (5.9) 233 (9.1) 0.28
Fluid and electolyte disorder 45 (44.6) 986 (38.4) 0.22
Depression 25 (24.8) 365 (14.2) 0.003*
Other neurological disorders 22 (21.8) 440 (17.2) 0.23
Bactremia 11 (10.9) 419 (16.3) 0.14
Skin/subcutaneous infection 32 (31.7) 638 (24.9) 0.12
Chronic ulcer 26 (25.7) 424 (16.5) 0.02*
Dialysis 18 (17.8) 285 (11.1) 0.04*
Pneumonia 67 (66.3) 1,612 (62.9) 0.48
Culture-confirmed infections with
Enterococcus 31 (30.7) 463 (18.1) 0.001*
VRE 20 (19.8) 218 (8.5) < 0.001*
Psudomonas aeruginosa 31 (30.7) 508 (19.8) 0.008*
Concomitant2) MRSA infection site
Blood 12 (11.9) 359 (14.0) 0.55
Bone 5 (5.0) 25 (1.0) 0.002*
Nares < 5 (<5.0) 112 (4.4) 1.00
Skin 20 (19.8) 404 (15.8) 0.27
Urine 9 (8.9) 183 (7.1) 0.50
Medical history3)
Previous Elixhauser score 5.4 ± 3.1 5.0 ± 3.0 0.24
Previous chronic renal disease 31 (30.7) 593 (23.1) 0.08
Previous diabetes 63 (62.4) 1,350 (52.6) 0.05*
Previous rheumatoid arthritis 5 (5.0) 56 (2.2) 0.07
Previous congestive heart failure 44 (43.6) 903 (35.2) 0.09
Previous hypothyroidism 16 (15.8) 248 (9.7) 0.04
Previous bactremia 7 (6.9) 115 (4.5) 0.25
Previous osteomyelitis 8 (7.9) 74 (2.9) 0.004*
Previous surgery/medical care complication 13 (12.9) 234 (9.1) 0.20
Previous allergy to vancomycin 9 (8.9) 14 (0.6) < 0.001*
Previous pneumonia 32 (31.7) 598 (23.3) 0.05*
Previous culture-confirmed infections with
Enterococcus 12 (11.9) 163 (6.4) 0.03*
VRE 6 (5.9) 48 (1.9) 0.004*
Data are mean ± standard deviation or number (%) of patients.  MRSA: Methicillin-Resistant Staphylococcus aureus; VRE: Vancomycin-Resistant Enterococcus
1. Present during the MRSA pneumonia hospitalization.
2. Present between the MRSA pneumonia admission and the end of treatment
3. Present in the 1 year prior to the admission with a positive MRSA pulmonary culture.
* p<0.05
Table 1:  Demographics and Comorbid Conditions by Treatment Group
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Healthcare and antibiotic exposures LinezolidN=101
Vancomycin
N=2,565 P-value
Hospital unit at treatment initiation
0.44Intensive care 39 (38.6) 895 (34.9)
General medicine / Other 62 (61.4) 1,669 (65.1)
Surgery during the current admission 46 (45.5) 1,039 (40.5) 0.31
MRSA culture site
0.01*Bronchial 13 (12.9) 165 (6.4)
Non-bronchial (i.e. lung) 88 (87.1) 2,400 (93.6)
Year
0.15
2002 5 (5.0) 112 (4.4)
2003 5 (5.0) 238 (9.3)
2004 10 (9.9) 271 (10.6)
2005 8 (7.9) 258 (10.1)
2006 5 (5.0) 247 (9.6)
2007 11 (10.9) 253 (9.9)
2008 16 (15.8) 253 (9.9)
2009 7 (6.9) 235 (9.2)
2010 16 (15.8) 234 (9.1)
2011 8 (7.9) 263 (10.2)
2012 10 (9.9) 201 (7.8)
Region of facility
0.23
Northeast 14 (13.9) 434 (16.9)
South 53 (52.5) 1,198 (46.7)
Midwest 24 (23.8) 515 (20.1)
West 10 (9.9) 418 (16.3)
Length of therapy (days) 8.3 ± 5.3 7.3 ± 5.9 0.08
Previous hospitalization, 90 days 38 (37.6) 991 (38.6) 0.84
Previous surgery, any, 90 days 22 (21.8) 324 (12.6) 0.01*
Previous nursing home stay, 90 days 7 (6.9) 166 (6.5) 0.85
Previous anti-MRSA antibiotic1)
Number of antibiotics 1.6 ± 0.6 1.3 ± 0.5 < 0.001*
Number of days with antibiotic use 13.3 ± 11.6 8.2 ± 9.4 0.01*
Linezolid 10 (9.9) 22 (0.9) <0.001*
Vancomycin 18 (17.8) 300 (11.7) 0.06
Other antibiotics 9 (8.9) 120 (4.7) 0.05*
Data are mean ± standard deviation or number (%) of patients.  MRSA: Methicillin-Resistant Staphylococcus aureus.
1. Present in the 90 days prior to the admission with a positive MRSA pulmonary culture.
* p<0.05
Table 2: Healthcare and Antibiotic Exposures and Hospitalization-Related Characteristics by Treatment Group
patients [15,27-30]. Two meta-analyses which compared vancomycin 
and linezolid for nosocomial pneumonia, found no differences in 
clinical and microbiologic outcomes or mortality [29,30]. While 
many trials have demonstrated equivalent efficacy between linezolid 
and vancomycin [12,14], a recent prospective, randomized, double-
blind trial of MRSA pneumonia demonstrated higher clinical and 
microbiologic success rates with linezolid over vancomycin, however 
mortality was similar between the two groups [15]. Although several 
studies have shown benefits for linezolid treatment compared with 
vancomycin [10,15,31], their methodological and statistical limitations 
have been frequently debated in the literature [32-34]. 
There is conflicting evidence surrounding treatment outcomes 
with vancomycin at higher MICs. Some studies suggest patients with 
MRSA infections are more likely to experience clinical success with 
vancomycin if the vancomycin MIC is < 1 μg/mL as compared to 
patients with higher MICs [35,36]. In an observational study of 158 
patients with hospital-acquired, ventilator-associated or healthcare-
associated MRSA pneumonia, mortality increased as a function of 
the vancomycin MIC [37]. The overall all-cause 28-day mortality rate 
in these patients was 32.3%, with the majority of isolates having a 
vancomycin MIC ≥ 1.5 μg/mL (115/158, 72.8%) [37]. However, a recent 
meta-analysis examining the association between vancomycin MIC 
and mortality rates in patients with Staphylococcus aureus bacteremia 
demonstrated no significant differences in mortality between patients 
with lower-vancomycin MICs (< 1.5 μg/mL) and those with higher-
MICs (≥ 1.5 μg/mL) [38]. 
In our sensitivity analyses, we observed significant differences 
between treatment groups when restricting the vancomycin group to 
patients with lower MICs (≤ 1 μg/mL). Linezolid was associated with 
a significantly lower discharge rate, representing an increased length 
of stay, a significantly decreased rate of therapy discontinuation, 
indicating longer therapy duration, and a significantly lower rate of 
30-day mortality, representing greater survival, as compared to the 
vancomycin group with MICs of ≤ 1 μg/Ml. We believe this is the 
first study to demonstrate improved outcomes with linezolid in obese 
patients, as compared to those receiving vancomycin and infected with 
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HR: Hazard Ratio; CI: Confidence Interval; ICU: Intensive Care Unit; MRSA: Methicillin-Resistant Staphylococcus aureus.
1. Adjusted by propensity score quintiles (reference quintile I).
2. Propensity score matched within 0.001 caliper.
The propensity score was derived from an unconditional logistic regression model controlling for age, body mass index, Elixhauser score, time to therapy initiation 
from culture date, year, region of facility, hospital unit at treatment initiation, culture site, history of MRSA infection, elevated white blood cell count, current diabetes 
complications, current myocardial infarction, current cerebrovascular disease, current rheumatoid arthritis, current hypertension, current other neurological disorders, 
current coagulopathy, current fluid and electolyte disorder, current depression, current skin infection, current chronic ulcer, current bacteremia, current immune disorder, 
current dialysis, current VRE infection, current Psudomonas aeroginosa infection, concomitant MRSA infection in bone, history of chronic renal disease, history of diabetes, 
history of cancer, history of congestive heart failure, history of hypothyroidism, history of burn, history of pneumonia, history of bacteremia, history of osteomyelitis, history 
of neutropenia, history of VRE infection, history of allergy to vancomycin, nursing home stay in previous 30 days, surgery in previous 90 days, linezolid in previous 90 days, 
trimethoprim/sulfamethoxazole in previous 90 days, daptomycin in previous 90 days, number of antibiotic used in previous 90 days (C-statistic 0.84). 
Table 3: Outcomes in Overall Cohort: Linezolid Compared with Vancomycin
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HR: Hazard Ratio; CI: Confidence Interval; BMI: Body Mass Index; ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification; MIC: Minimum 
Inhibitory Concentration.
1. Adjusted by propensity score quintiles (reference quintile I).
2. Propensity score matched within 0.001 caliper. 
Table 4: Subgroup and Sensitivity Analyses: Linezolid Compared with Vancomycin
low MIC strains. On the contrary, there were no significant differences 
in clinical outcomes between treatment groups when restricting the 
vancomycin group to those with vancomycin MICs of ≥ 1.5 μg/mL. 
Since this was a national study, MIC testing systems varied by facility 
and MIC testing methodology was not specified in the data. 
Appropriate dosing of antibiotics in obese patients is extremely 
difficult and may result in underdosing [9,39]. Furthermore, 28% of our 
cohort had a diagnosis of chronic renal disease during the admission, 
which further complicates appropriate dosing in the obese population. 
Obese patients treated with vancomycin may be less likely to achieve 
optimal dosing, which puts patients at risk for poor outcomes [40], 
even if they had a favorable vancomycin susceptibility. 
Vancomycin trough concentrations of 15-20 mg/L are 
recommended for severe infections, including MRSA pneumonia, 
in order to improve penetration, increase the probability of optimal 
serum vancomycin concentrations, and improve clinical outcomes 
[25]. However the optimal trough in obese patients is largely unknown. 
Among patients with true vancomycin trough concentrations, only 22% 
(n=66) were in therapeutic range. All clinical outcomes were similar 
in patients with vancomycin trough levels of 15-20 mg/L compared 
to patients receiving linezolid. Although we found no significant 
differences between linezolid and vancomycin, the relatively small 
number of patients with true trough levels of 15-20 mg/L may have 
affected our ability to detect differences between the treatment groups. 
There is always the potential for observational studies to be 
impacted by bias and residual confounding. To address these potential 
limitations, we took steps in the design and analytic phases to minimize 
bias. To capture potential confounders, we assessed a variety of patient 
data, including pharmacy data, microbiology data, and records of 
inpatient and outpatient care. To address the impact of confounding by 
indication, we utilized propensity score methods in the analytic phase 
[20,21,41]. Although balance was achieved within propensity score 
quintiles and between propensity matched pairs, there is the potential 
for residual confounding by unobserved covariates. Additionally, due 
to the relatively small sample size after matching propensity scores, we 
may have been unable to detect small differences in clinical outcomes 
between the two treatment groups. 
Though we sought to develop accurate definitions for exposures, 
outcomes, and known potential confounders, misclassification bias 
may have impacted our study results. Our definition of suspected 
MRSA pneumonia may not have captured all MRSA pneumonia 
infections. Previous research has shown that as many as 30% of patients 
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never have cultures taken [27]. In addition, we included patients with 
positive MRSA respiratory cultures from both sputum and BAL. The 
sensitivity of culture-positive isolates from non-bronchoscopic lung 
lavage for confirming ventilator-associated pneumonia is reported 
to be 72% with a Positive Predictive Value (PPV) of 14%, while the 
sensitivity of BAL for confirming pneumonia is 89% with a PPV of 
33% [42]. Since our cohort definition for suspected MRSA pneumonia 
was based on culture confirmation and the presence of clinical signs 
of infection, we performed a subgroup analysis restricting the cohort 
to patients with a pneumonia diagnosis code in addition to a positive 
culture from a respiratory culture site and clinical signs of infection. 
This subgroup analysis demonstrated consistent results with those of 
the overall cohort. 
Lastly, our study findings were further impacted by the limited 
generalizability of the VA population to the general US population. 
However, the Veterans Health Administration is the largest integrated 
healthcare system in the US. Due to the implementation of electronic 
medical records in 1999, large standardized databases, unique in size 
and content, include a wealth of information not available from other 
national data sources, including barcode medication administration, 
microbiology, and lab chemistry data [43]. 
Conclusions
We evaluated the effectiveness of linezolid therapy compared to 
vancomycin in obese patients with culture-confirmed MRSA from 
a pulmonary site and found no significant differences in clinical 
outcomes between the two treatment groups. In sensitivity analyses, 
however, we found that linezolid was associated with a significantly 
higher survival rate compared to vancomycin patients with lower 
MICs (≤ 1 μg/mL). Based on our review of the literature, this is the first 
study to demonstrate improved survival with linezolid as compared to 
vancomycin among obese patients with suspected MRSA pneumonia 
infected with low vancomycin MICs. As such, further studies are 
needed to determine whether this beneficial effect is observed in other 
study populations and to determine the clinical implications of this 
finding.
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